Phytosome - Enabled Delivery of Ellagic Acid: A Comprehensive Review of Formulation, Characterization, and Therapeutic Potential

Ellagic acid (EA), a naturally occurring polyphenolic compound, has garnered significant attention in recent decades for its diverse pharmacological properties and potential therapeutic applications. Primarily derived from hydrolysable tannins known as ellagitannins found in various fruits, nuts, and plants, EA exhibits potent antioxidant, anti-inflammatory, anticancer, and other bioactive effects. Despite its promising health benefits, including protection against oxidative stress, inflammation, and chronic diseases such as cancer and metabolic disorders, the clinical utility of conventional EA is hindered by challenges related to bioavailability. These limitations have spurred research into advanced delivery systems to enhance its efficacy and therapeutic potential [1].

1. 1. Natural sources of ellagic acid and chemical structure

Ellagic acid (EA) is a naturally occurring polyphenolic compound widely distributed in flowering plants and is predominantly present as hydrolysable tannins known as ellagitannins, which release free EA upon acid- or base-catalysed hydrolysis. EA represents an important dietary polyphenol owing to its widespread occurrence in edible and medicinal plant species. Dietary intake of EA is mainly derived from fruits and berries, where total EA and ellagitannin contents typically range from 100 to 1500 mg/kg dry weight. Pomegranate (Punica granatum) is among the richest sources of EA, with exceptionally high concentrations reported in the peel and mesocarp. Berries such as raspberries, strawberries, blackberries, cloudberries, and muscadine grapes also contain substantial amounts of EA, particularly concentrated in the fruit skin.¹ Kakadu plum (Terminalia ferdinandiana) has been identified as one of the richest edible sources of EA, with levels reaching up to 140 g/kg dry weight. Camu-camu (Myrciaria dubia) fruit flour also represents a significant source of EA, containing more than 5600 mg/kg dry weight. In addition to fruits, EA is present in nuts and seeds such as walnuts, pecans, and almonds. Agro-forestry and wood-processing by-products serve as important industrial sources of EA and ellagitannins, particularly in tannin-rich tree species. Significant levels of EA have been reported in the bark and wood of Eucalyptus species, sweet chestnut (Castanea sativa), and oak (Quercus spp.). EA is highly abundant in medicinal plants, and is commonly used as a chemotaxonomic marker, particularly in the Rosaceae family. Geraniaceae family and other tannin-rich species EA is produced by the hydrolysis of compounds like geraniin [1].

Fig. 1. Chemical structure of ellagic acid (2,3,7,8-tetrahydroxy-chromeno[5,4,3-cde] chromene-5,10-dione; molecular formula: C??H?O?).

1. 2. Pharmacological Properties of Ellagic Acid

Ellagic acid (EA) is a naturally occurring polyphenolic compound that demonstrates a broad spectrum of pharmacological activities, supported by extensive in vitro, in vivo, and some clinical studies. These effects are largely attributed to its potent antioxidant and anti-inflammatory properties, with therapeutic potential in diverse pathological conditions, including cancer, metabolic disorders, neurodegenerative diseases, inflammatory conditions, infections, cardiovascular diseases, and dermatological disorders [2].

Fig. 2. Mechanistic overview of ellagic acid–mediated therapeutic and protective effects

Among its most intensively investigated actions are the anticancer and chemo preventive effects against various malignancies, including prostate, colon, breast, skin, ovarian, brain, oesophageal, lung, and liver cancers. EA exhibits antiproliferative, antimutagenic, and pro-apoptotic effects, inhibiting cancer cell growth through multiple mechanisms such as inhibition of procarcinogen activation, scavenging of reactive carcinogenic species, prevention of DNA damage, cell cycle arrest, angiogenesis inhibition, and suppression of metastasis. It induces mitochondrial-dependent apoptosis via modulation of the Bax/Bcl-2 ratio, activation of caspases, regulation of tumour suppressor proteins like p53 and p21, and inhibition of oncogenic signalling pathways, including NF-κB and c-Myc. As one of the most potent natural antioxidants, EA functions by directly scavenging reactive oxygen and nitrogen species (ROS/RNS), inhibiting lipid peroxidation, chelating transition metal ions involved in oxidative reactions, and modulating endogenous antioxidant enzymes such as superoxide dismutase and catalase. It further enhances antioxidant defence systems through activation of the Nrf2/HO-1 signalling pathway [3].

Fig. 3. Molecular mechanisms underlying the antioxidant effects of ellagic acid

The anti-inflammatory effects of EA involve suppression of pro-inflammatory cytokines (e.g., TNF-α, IL-6) and inhibition of key inflammatory mediators and pathways, such as COX-2, iNOS, and NF-κB, demonstrating benefits in conditions like asthma and cardiovascular diseases [3].

Fig. 4. Anti-inflammatory mechanisms of ellagic acid, highlighting NF-κB inhibition pathyway

EA also exhibits broad anti-infective and antihelminthic (anthelmintic) activities. In vitro studies have demonstrated its efficacy against helminth parasites, including nematodes such as Haemonchus contortus (via adult motility inhibition and egg hatch assays), Onchocerca ochengi, and drug-resistant strains of Caenorhabditis elegans. EA shows promising potential against anthelmintic-resistant nematodes, with low toxicity profiles. This activity is often linked to polyphenolic interference with parasite motility, viability, and reproductive processes, potentially through tannin-related mechanisms or direct disruption of parasite physiology. Additionally, EA contributes to broader antiparasitic effects in plant extracts against various helminths [4]. Other properties include neuroprotective effects in models of Alzheimer’s and Parkinson’s diseases through attenuation of oxidative stress and neurotoxic pathways; hepatoprotective and antidiabetic activities via improved glycaemic control, enhanced insulin secretion, and reduced advanced glycation end products; broad antimicrobial and anti-infective effects against bacterial, viral (e.g., HIV, influenza), and other parasitic (e.g., Plasmodium) pathogens; anti-obesity effects; and dermatological/cardiovascular benefits through photoprotective, anti-aging, anti-atherogenic, and cardioprotective mechanisms. These multifaceted actions are often interconnected through EA's core ability to mitigate oxidative stress and inflammation [5].

Fig. 5. Comprehensive schematic of ellagic acid's pharmacological mechanisms across multiple therapeutic areas.

1.3 Limitations of Conventional Ellagic Acid Delivery

Despite its broad pharmacological potential, the clinical translation of ellagic acid (EA) is markedly constrained by unfavourable physicochemical and pharmacokinetic properties that result in poor gastrointestinal absorption and low systemic bioavailability. Conventional oral administration of EA and its naturally occurring precursors, ellagitannins (ETs), therefore fails to reliably achieve therapeutically effective concentrations, limiting its utility as a chemo preventive or therapeutic agent. EA exhibits extremely low aqueous solubility and limited intestinal permeability, which severely restrict its gastrointestinal absorption. Reported solubility values of EA are as low as 9.7 μg/mL at physiological temperature, classifying it as a Biopharmaceutics Classification System (BCS) Class IV compound characterized by both low solubility and low permeability. Although EA solubility increases modestly under neutral or alkaline conditions, its phenolic structure renders it chemically unstable and susceptible to oxidative degradation at elevated pH. EA also demonstrates poor solubility under gastric conditions, further compromising oral absorption. Ellagitannins are relatively resistant to acidic hydrolysis and are predominantly degraded in the small intestine, resulting in delayed release of free EA. Following absorption, EA exhibits limited systemic availability due to inefficient intestinal uptake and extensive first-pass metabolism. Pharmacokinetic studies indicate rapid conversion of EA into methylated and glucuronide conjugates, leading to a short plasma half-life and low circulating concentrations. In humans, peak plasma concentrations of EA following consumption of EA-rich foods typically remain in the nanogram-per-millilitre range. Interindividual variability in EA metabolism represents an additional challenge to clinical translation. Unabsorbed EA and ETs are metabolized by colonic microbiota into urolithins, the production of which is highly dependent on individual gut microbial composition. This metabolism type-dependent variability contributes to inconsistent biological responses and unpredictable therapeutic outcomes. Furthermore, formulation-related challenges hinder clinical application, as EA is poorly soluble in most conventional solvents and exhibits limited stability in aqueous systems. Currently available commercial formulations, including tablets, capsules, and beverages, fail to adequately overcome these delivery limitations [6].

1.4 Need for Novel Delivery Systems for Ellagic Acid

The development of novel delivery systems for ellagic acid (EA) is primarily driven by its unfavorable physicochemical and pharmacokinetic characteristics, which significantly limit its therapeutic efficacy following conventional oral or topical administration.? Despite its well-documented pharmacological potential, EA exhibits extremely poor solubility, low permeability, rapid metabolism, and formulation instability, resulting in inadequate systemic exposure and inconsistent therapeutic outcomes. EA is classified as a Biopharmaceutics Classification System (BCS) Class IV compound due to its very low aqueous solubility and poor intestinal permeability. Its solubility has been reported to be as low as 9.7 μg/mL at physiological temperature, which severely restricts gastrointestinal absorption and leads to minimal plasma concentrations following oral administration. Clinical studies have demonstrated that even after consumption of EA-rich foods such as pomegranate juice, circulating EA levels remain extremely low, indicating that conventional dosage forms are insufficient to overcome absorption barriers. Furthermore, intestinal uptake of EA appears to be saturable, such that increasing the administered dose does not proportionally enhance bioavailability, thereby limiting its effectiveness as an in vivo chemo preventive or therapeutic agent. Besides decreased absorption, EA also has a low plasma half-life and a limited pharmacological action time, which is further worsened by a lack of chemical stability in solution, where hydrolytic and oxidative breakdowns occur during storage. Moreover, marked interindividual variability in gut microbiota–mediated metabolism of EA and ellagitannins leads to inconsistent formation of bioactive urolithins, resulting in variable therapeutic responses among individuals.

To fully exploit the broad therapeutic and prophylactic potential of EA—including its anticancer, antidiabetic, neuroprotective, and dermatological effects—advanced drug delivery strategies are essential. Novel micro- and nanotechnology-based systems have been proposed to enhance solubility and stability, improve intestinal and dermal permeability, reduce first-pass metabolism, and achieve sustained and targeted delivery. So, these approaches aim to maintain effective therapeutic concentrations of EA at target sites, thereby overcoming the limitations of conventional formulations and enabling its successful clinical translation [7].

2. PHYTOSOME TECHNOLOGY: PRINCIPLES AND MECHANISM

The mechanism involves hydrogen bonding between the polar groups of the phytochemical and the phospholipid's choline head, while hydrophobic tails provide lipid compatibility. This confers dual solubility, better membrane permeation, and up to 20-fold bioavailability improvement. Unlike liposomes (where actives are encapsulated in aqueous cores), phytosomes feature chemical bonding for greater stability and efficacy.

Fig. 6. Structural organization of a phytosome

2.1 Concept and Evolution of Phytosomes

Phytosomes (also known as herbosomes or phyto-phospholipid complexes) are an advanced vesicular drug delivery system designed to enhance the absorption of water-soluble phytochemicals, particularly polyphenolic compounds. The term "phytosome" derives from "phyto" meaning plant and "some" referring to cell-like structures.Phytosomes are formed through stoichiometric interactions between phospholipids, such as phosphatidylcholine, and polyphenolic phytochemicals in non-aqueous solvents, resulting in supramolecular complexes stabilized primarily by hydrogen bonding and hydrophobic interactions. These amphiphilic complexes readily integrate into cellular lipid bilayers, significantly improving gastrointestinal absorption compared to free phytochemicals.The concept originated in the 1980s from histochemical observations of natural affinities between plant polyphenols (e.g., anthocyanins) and membrane lipids, leading to the patenting of phytosome technology in 1989 by Indena S.p.A., an Italian firm. The primary goal is to overcome poor oral bioavailability of high-molecular-weight, poorly lipid-soluble flavonoids and tannins, which struggle to cross biological barriers.

Early developments used solvent precipitation methods, evolving to advanced techniques like supercritical fluid extraction and anti-solvent precipitation for compounds such as ellagic acid. Initial applications focused on nutraceuticals (e.g., liver support), while recent advancements incorporate targeted delivery for conditions like PCOS, skin disorders, and cancer. For instance, ellagic acid-loaded phytosomes enhance pharmacokinetics by improving water solubility, reducing metabolism, and amplifying antioxidant and anti-inflammatory effects.This technology bridges modern novel drug delivery systems with traditional herbal medicine, enabling controlled release, localized action, and reduced side effects [8].

2.2 Phospholipid–Phytoconstituent Interaction Mechanism

Phytosome creation relies on non-covalent interactions, primarily hydrogen bonds and van der Waals forces, between phospholipids and phytoconstituents, without altering the chemical structures of either component. Phospholipids like phosphatidylcholine (PC) and phosphatidylethanolamine (PE) feature a hydrophilic polar head and two hydrophobic fatty acid tails. Phenolic phytochemicals, such as ellagic acid (EA) with its hydroxyl and lactone groups, provide polar sites for hydrogen bond donation and acceptance.

Fig. 7. Mechanism of phytosome-mediated enhancement of solubility, bioavailability, and targeted drug delivery

Complexation involves mixing the phytoconstituent and phospholipid in an aprotic solvent at a stoichiometric ratio of 1:1 to 1:4. Hydrogen bonds form between the phytoconstituent's hydroxyl groups and the phospholipid's polar head, while the lipid tails enclose the complex, yielding an amphiphilic, planar structure where the active is integrated into the membrane rather than encapsulated.FTIR spectroscopy reveals shifts in –OH and C=O stretching, confirming hydrogen bonds without covalent changes. NMR analysis shows phospholipid tails shielding the phytoconstituent's core, enhancing lipophilicity.For EA, its four hydroxyl groups and lactone rings interact with soya lecithin's phosphate moieties, forming stable precipitates via anti-solvent addition (e.g., n-hexane). This boosts solubility, protects against digestive degradation, and facilitates gut epithelial crossing into circulation.In water, phytosomes self-assemble into nanoscale vesicles (50–200 nm) with liposome-like properties but superior stability due to chemical bonding [9].

2.3 Comparison with Liposomes, Nanoemulsions, and Polymeric Nanoparticles

Phytosomes are especially well-suited for the delivery of phytoconstituents because they differ from other NDDS in terms of structure, preparation, and performance, but they share vesicular characteristics.

Table. 1. Comparative analysis of phytosomes and other nanocarrier-based delivery systems for phytoconstituent delivery

Fig. 8. Comparative schematic representation of phytosome and liposome

Due to stable hydrogen bonding, phytosomes offer superior stability and membrane fusion compared to liposomes, better physiological compatibility than polymeric nanoparticles, and enhanced cellular uptake over simpler nanoemulsions.

2.4 Advantages of Phytosomes (Enhanced Bioavailability, Membrane Permeability, Improved Stability)

For phytoconstituents such as ellagic acid (EA), which exhibit extremely low water solubility (<1 μg/mL), rapid metabolism, and poor oral bioavailability (typically 5–10%), phytosomes provide significant advantages over conventional herbal formulations.

• Enhanced Bioavailability: Phytosomes form lipophilic complexes that facilitate transcellular absorption across the intestinal epithelium, resulting in 2- to 5-fold increases in plasma area under the curve (AUC). Improved wettability and reduced first-pass metabolism enable rapid and near-complete dissolution (e.g., >95% within 120 minutes for optimized EA-phytosomes versus <20% for free EA). Clinically validated examples, such as silybin phytosomes, demonstrate superior hepatic targeting and systemic exposure.
• Enhanced Membrane Permeability: The amphiphilic nature of phytosomes closely mimics cell membranes, promoting passive diffusion and endocytosis. Hydrogen bonding integrates the phytoconstituent into lipid bilayers, dramatically improving penetration across biological barriers. Notable examples include 3–4-fold higher transdermal flux for EA formulations and enhanced blood-brain barrier crossing for neuroprotective applications. In metabolic disorders like PCOS, targeted ovarian delivery has been shown to restore insulin sensitivity via modulation of PI3K/Akt signaling pathways.
• Improved Stability: Strong molecular interactions confer exceptional resistance to oxidation, enzymatic degradation, and pH variations in the gastrointestinal tract, with drug leakage typically below 10% in simulated fluids. EA-phytosomes routinely achieve entrapment efficiencies exceeding 80% and maintain integrity against bile salts, outperforming liposomes. This enhanced stability supports prolonged shelf life, reduced dosing frequency, and minimized side effects, making phytosomes ideal for chronic therapies.

Overall, these benefits position phytosomes as a powerful bridge between modern precision drug delivery and traditional herbal medicine, expanding therapeutic applications in dermatology, oncology, metabolic disorders, and beyond [11, 12].

3. METHODS FOR PREPARATION OF PHYTOSOMES

Phytosomes represent an advanced vesicular drug delivery system designed to enhance the bioavailability of poorly soluble polyphenolic compounds like ellagic acid (EA). These complexes are formed through non-covalent interactions, primarily hydrogen bonding, between the polar head groups of phospholipids (such as phosphatidylcholine) and the hydroxyl groups of polyphenols. This amphiphilic nature allows phytosomes to traverse biological membranes more efficiently than free EA, which suffers from low aqueous solubility (<10 μg/mL), poor permeability, and rapid metabolism. The preparation methods leverage phospholipid complexation to create stable nano-sized carriers, often resulting in 5–10-fold improvements in solubility and 2–3-fold enhancements in oral bioavailability for similar polyphenols [13].

3.1 Solvent Evaporation Method

The solvent evaporation method, also known as rotary evaporation or thin-film formation, is one of the most conventional and scalable techniques for phytosome preparation. It involves dissolving EA (or EA-rich extracts) and phospholipids in a volatile organic solvent, followed by controlled evaporation to form a thin lipid film, which facilitates intimate molecular complexation.

Procedure:

• EA and phospholipid (typically soy or hydrogenated soy phosphatidylcholine, HSPC) are co-dissolved in an aprotic solvent such as dichloromethane, acetone, ethanol, or methanol at molar ratios ranging from 1:1 to 1:4.
• The mixture is refluxed at 40–60°C for 1–4 hours under magnetic stirring (300–500 rpm) to promote hydrogen bonding between EA's phenolic hydroxyls and the phospholipid's choline or phosphate groups.
• The solvent is evaporated under reduced pressure using a rotary evaporator (e.g., at 40–50°C, 100–200 rpm) to deposit a uniform thin film on the flask wall.
• Residual solvent is removed by vacuum drying or nitrogen flushing for 12–24 hours.
• For vesicular phytosomes, the film is hydrated with aqueous media (e.g., phosphate buffer pH 6.8) under rotation or sonication, yielding multilamellar vesicles that can be downsized via extrusion or probe sonication.

Advantages and Outcomes:

This method yields high complexation efficiency (>90% in optimized cases) and stable complexes with particle sizes of 100–500 nm. Studies on analogous polyphenols (e.g., curcumin, silybin) show enhanced lipophilicity and antioxidant activity. For EA specifically, adaptations have produced complexes with improved dissolution rates. Variations include combining with hyaluronic acid for ocular delivery or pegylation for targeted therapy.

Limitations:

Potential residual solvent toxicity requires thorough removal; heat-sensitive compounds may degrade if temperatures exceed 60°C [14].

Fig. 9. Schematic representation of liposome preparation by rotatory evaporator i.e. Solvent Evaporation method

3.2 Anti-Solvent Precipitation Method

The anti-solvent precipitation method is favoured for producing smaller, more uniform nanoparticles with high entrapment efficiency, making it ideal for EA's poor solubility profile.

Procedure:

• EA and phospholipid are dissolved in a water-miscible organic solvent (e.g., ethanol, tetrahydrofuran, or acetone) at 40–60°C.
• The solution is stirred or refluxed for 1–2 hours to initiate complexation.
• An anti-solvent (e.g., n-hexane, deionized water, or petroleum ether) is added dropwise or rapidly under vigorous stirring (1000–2000 rpm) to induce instantaneous precipitation of the EA-phospholipid complex.
• The precipitate is centrifuged (10,000–15,000 rpm, 15 min), washed multiple times to remove uncomplexed material, and dried via lyophilization or vacuum drying.
• Optional sonication or homogenization refines particle size.

Advantages and Outcomes:

This technique often achieves particle sizes <100 nm, entrapment efficiencies >95%, and superior dissolution (up to 10-fold increase). Direct applications to EA include phospholipid complexes integrated into self-nanoemulsifying drug delivery systems (SNEDDS), demonstrating 2–3-fold higher ex vivo permeation and overcoming food effects on absorption. It is scalable and minimizes thermal degradation.

Limitations:

Requires careful anti-solvent selection to avoid incomplete precipitation; rapid addition can cause aggregation [15].

Fig. 10. Schematic representation of phytosome preparation by antisolvent precipitation

3.3 Thin-Film Hydration Method

This method, often overlapping with solvent evaporation, emphasizes hydration to form vesicular structures (phytosomal liposomes) and is commonly used for polyphenol extracts containing EA.

Procedure:

• Similar initial steps to solvent evaporation: co-dissolution and refluxing, followed by rotary evaporation to form a thin film.
• The dried film is hydrated with aqueous buffer (e.g., PBS pH 7.4) at 50–60°C above the phospholipid's transition temperature, under gentle rotation or vortexing.
• Multilamellar vesicles form spontaneously; size reduction via probe sonication, bath sonication, or extrusion through polycarbonate membranes (100–200 nm pores) yields unilamellar phytosomes.
• Cryoprotectants (e.g., mannitol) may be added for lyophilization.

Advantages and Outcomes:

Produces stable vesicles with high entrapment (80–95%) and controlled release. Applied to EA-rich extracts (e.g., from Callistemon citrinus or pomegranate), it enhances stability and anti-obesity effects in vivo. Thin-layer sonication variants reduce sizes further for better penetration.

Limitations:

Multistep process; potential oxidation during hydration requires inert atmosphere [16].

Fig. 11.  Schematic representation of liposome preparation by thin-film hydration followed by sonication

3.4 Lyophilization (Freeze-Drying) Method

Lyophilization is typically an adjunct for drying and stabilizing phytosomes post-formation but can be a primary method when combined with co-solvency.

Procedure:

• Complex suspension from other methods is mixed with cryoprotectants (e.g., trehalose, sucrose 5–10% w/v).
• Frozen at –40 to –80°C, then primary drying under vacuum (0.1–0.5 mbar) followed by secondary drying.
• Reconstitutable powders result.

Advantages:

Enhances shelf-life (up to years) and prevents aggregation. Often paired with anti-solvent for EA complexes, yielding redispersible nanosuspensions.

This table [Table] compares the key preparation methods for ellagic acid (EA) phytosomes, summarizing process parameters, performance metrics, advantages, limitations, and applications [17].

Table. 2. Comparative Analysis of Phytosome Preparation Methods for Ellagic Acid

3.5 Factors Affecting Phytosome Formation

Optimization is critical for maximizing complex yield, stability, and bioavailability. Key parameters include:

1. Drug–Lipid Ratio: Molar ratios of 1:1 to 1:3 are optimal; excess phospholipid increases size and entrapment but reduces loading. For EA, 1:2–1:4 ratios balance solubility enhancement without phase separation.
2. Solvent Selection: Aprotic solvents (dichloromethane, acetone) favor complexation; protic solvents disrupt hydrogen bonds. Residual solvents must comply with ICH limits (<5000 ppm).
3. Temperature: 40–60°C optimal; higher risks EA degradation (thermolabile at >70°C), lower slows bonding.
4. Reaction Time and Stirring: 1–4 hours with 300–1000 rpm; prolonged time improves yield but may aggregate.
5. Hydration Conditions: pH (6–7.4), volume, and agitation affect vesicle uniformity; sonication reduces polydispersity.
6. Other Factors: Phospholipid source (soy vs. egg), purity (>90% phosphatidylcholine), and drying method influence zeta potential and stability.

Statistical tools like factorial design or response surface methodology optimize these for >95% entrapment and <200 nm size.

3.6 Critical Process Parameters and Method Selection Rationale

Scalability and Reproducibility: Solvent evaporation and anti-solvent are GMP-compatible and scalable; thin-film hydration suits lab-scale vesicular forms.

Particle Size and Bioavailability: Anti-solvent yields smallest sizes (<100 nm), ideal for EA's intestinal absorption; solvent evaporation for controlled release.

Stability and Yield: Lyophilization ensures long-term stability; high yields (>90%) from all methods with optimization.

Rationale for EA Phytosomes: Anti-solvent preferred for rapid, high-bioavailability complexes (e.g., SNEDDS integration); solvent evaporation for simple, high-loading formulations. Emerging supercritical anti-solvent offers greener alternatives. Overall, these methods transform EA from a poorly bioavailable compound (absolute bioavailability <1%) into therapeutically viable forms, with pharmacokinetic studies showing prolonged plasma levels and enhanced tissue distribution.

4. FORMULATION STRATEGIES FOR ELLAGIC ACID PHYTOSOMES

4.1 Types of Phospholipids Used (Lecithin, Phosphatidylcholine)

Phytosomes are lipid-compatible molecular complexes designed to enhance the solubility and bioavailability of poorly water-soluble plant bioactives like ellagic acid (EA). Phospholipids such as lecithin and phosphatidylcholine (PC) serve as the structural backbone of these vesicular systems due to their amphiphilic nature, biocompatibility, and membrane-mimetic properties. Lecithin is a naturally derived mixture of phospholipids predominantly phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol typically obtained from soy or egg sources. In EA phytosomes, soy lecithin forms hydrogen bonds with the hydroxyl groups of ellagic acid, enhancing complexation efficiency and promoting better dispersion in lipid environments. Studies have demonstrated that the hydrogen bonding between EA and lecithin improves both in vitro release and in vivo absorption by increasing membrane permeability and protecting the compound from enzymatic degradation. Phosphatidylcholine, the most abundant component of lecithin, is particularly preferred in phytosomal formulations due to its zwitterionic nature and strong ability to form stable bilayers that facilitate drug-lipid interactions. PC interacts with ellagic acid through electrostatic and hydrogen bonding forces, leading to the formation of a compact complex with improved physicochemical stability and lipid solubility. Phosphatidylcholine-based phytosomes have shown enhanced Cmax and AUC values for various polyphenols, indicating superior systemic bioavailability [18].

Table. 3. Comparison of commonly used phospholipids in ellagic acid phytosome formulations.

4.2 Optimization Parameters (Drug–Lipid Ratio, Temperature, Hydration Time)

Optimizing formulation parameters is essential to achieve maximum complexation efficiency and desired physicochemical characteristics of EA phytosomes. The drug–lipid ratio, temperature, and hydration time significantly influence entrapment efficiency, particle size, and release profile.The drug–lipid ratio determines the degree of complex formation between EA and phospholipids. Studies have reported optimal ratios between 1:1 and 1:2 (EA: phospholipid, molar basis), where higher lipid content enhances complexation yield and dissolution but may increase particle size. It was found that an EA:lecithin ratio of 1:2 produced optimal solubility enhancement and sustained drug release up to 96% after 120 minutes. Beyond this ratio, excess lipid tends to form multilamellar aggregates, decreasing uniformity.Temperature plays a crucial role in facilitating solvent evaporation and molecular interaction between EA and the lipid phase. Moderate heating (40–60 °C) promotes phospholipid dispersion and complexation without causing degradation of ellagic acid, which is thermolabile. Maintaining the solvent removal step under controlled temperatures ensures consistent lipid matrix formation and avoids crystallization of free EA.Hydration time governs vesicle formation and stability. Longer hydration periods (≥30 min) allow for complete swelling of the lipid matrix, leading to well-defined, uniform vesicles with improved zeta potential and dispersion stability. Optimization tools such as response surface methodology (RSM) have been successfully used to study the combined effects of these parameters on encapsulation efficiency and release kinetics [19].

4.3 Challenges in Formulation and Scale-Up

Despite promising laboratory results, the scale-up and industrial production of ellagic acid phytosomes remain challenging. The process involves multiple critical steps solvent evaporation, hydration, homogenization, and drying each sensitive to minor deviations that can impact reproducibility.One of the major challenges is maintaining consistency in drug–lipid interactions on a large scale. Variations in phospholipid purity, solvent removal rates, and hydration uniformity can alter the final product’s particle size and entrapment efficiency (25). Additionally, ellagic acid’s poor solubility and multiple hydroxyl groups make it prone to oxidative degradation during processing and storage.Scale-up difficulties also arise due to differences in mixing efficiency and solvent recovery when transitioning from batch to continuous processing systems (27). Traditional methods such as rotary evaporation are not easily adaptable for high-throughput production, leading to inconsistent product quality. Emerging technologies like supercritical fluid extraction, microfluidization, and spray-drying have been investigated as alternatives to ensure better control and reproducibility.Moreover, regulatory challenges exist for phytosome-based formulations since they lie at the intersection of nutraceuticals and pharmaceuticals, often requiring additional bioequivalence and stability studies. Long-term stability testing, scalability assessments, and standardization of phospholipid sources remain key prerequisites for successful commercialization [20].

5. CHARACTERIZATION AND QUALITY EVALUATION

Characterization of ellagic acid (EA) phytosomes is essential to confirm successful complexation, ensure nanoscale properties, evaluate drug loading, assess structural changes, visualize morphology, understand release behavior, and verify stability. These techniques collectively demonstrate the advantages of phytosomal formulation over free EA, including improved solubility, altered crystallinity, and enhanced colloidal stability [21].

5.1 Physicochemical Characterization (Particle Size, PDI, Zeta Potential)

Dynamic light scattering (DLS) is the primary method for determining particle size, polydispersity index (PDI), and zeta potential in EA phytosomes.

1. Particle Size and PDI: Phytosomes typically exhibit hydrodynamic diameters in the range of 50–300 nm, depending on preparation method (e.g., smaller sizes <100 nm from anti-solvent precipitation). A low PDI (<0.3) indicates uniform monodisperse distribution, crucial for reproducible bioavailability and cellular uptake. Nano-sized particles facilitate passive targeting via enhanced permeability and retention (EPR) effect in tumors.
2. Zeta Potential: Values often range from –20 to –40 mV due to the negative charge of phosphatidylcholine's phosphate group, providing electrostatic repulsion that prevents aggregation. Higher absolute values (>30 mV) correlate with better physical stability in suspension. Surface modifications (e.g., PEGylation) can modulate zeta potential for prolonged circulation.

These parameters confirm the formation of stable nanosystems and predict in vivo performance, with smaller sizes and lower PDI linked to higher oral absorption of EA [22].

5.2 Entrapment Efficiency Determination

Entrapment efficiency (EE) quantifies the amount of EA incorporated into the phytosome complex versus free drug. Common methods include ultracentrifugation, dialysis, or size-exclusion chromatography to separate unbound EA, followed by quantification via UV-Vis spectrophotometry (λ_max ~360 nm for EA) or HPLC.

EE is calculated as: EE (%) = (Total EA – Free EA) / Total EA × 100.

Reported values for EA phytosomes exceed 80–95%, significantly higher than conventional liposomes, due to strong hydrogen bonding and hydrophobic interactions. High EE minimizes drug loss and ensures therapeutic doses, contributing to dose reduction and reduced side effects [23].

5.3 Solid-State and Structural Characterization (FTIR, DSC, XRD)

These spectroscopic and thermal techniques provide evidence of molecular interactions and amorphous transformation in phytosomes.

1. Fourier-Transform Infrared Spectroscopy (FTIR): Confirms complexation by shifts or broadening of peaks. Free EA shows sharp O–H stretching (~3400 cm?¹) and C=O (~1700 cm?¹); in phytosomes, these shift or diminish due to hydrogen bonding with phospholipid's polar head, while phospholipid C–H peaks (~2900 cm?¹) remain.
2. Differential Scanning Calorimetry (DSC): Free EA exhibits a sharp endothermic peak (~450°C melting); phytosomes show disappearance or broadening of this peak, indicating amorphization and molecular dispersion within the lipid matrix. Phospholipid transitions may also shift.
3. X-Ray Diffraction (XRD): Crystalline EA displays sharp Bragg peaks; phytosomes show halo patterns or reduced peak intensity, confirming conversion to amorphous state, which enhances solubility and dissolution rate.

These changes validate non-covalent complexation without chemical alteration of EA. The following table [Table] summarizes and visually depicts the advanced characterization methods for phytosomes or similar phospholipid complexes [24].

Table. 4. Comparative Analysis of Advanced Characterization Techniques for Ellagic Acid Phytosomes